OPTIMIZERx CORPORATION

Transcription

1 CORPORATE PROFILE OPTIMIZERx CORPORATION company opportunity The company is uniquely positioned as the market leader to leverage two very important trends in the $300 billion annual US pharmaceutical market: Increasing challenge of promoting products to doctors via restriction of drug reps and drug samples (only 54% of doctors were accessible according to latest research) Dramatic growth of electronic prescriptions that will reach 2 billion annually. The company offers health systems and pharmaceutical manufacturers a better alternative to drug samples by adding patient sample vouchers, co-pay coupons and patient education to the electronic prescription without any interruption to the doctors workflow. company history The company was founded in 2006 by a group of pharmaceutical veterans and physicians recognizing the poor utilization of available resources by consumers and physicians. A key driving force in forming the company was the escalating cost of drugs for patients, resulting in non- compliance with medication utilization. The founders were also aware that there is a lack of awareness and utilization of free sample vouchers and available free co-pay support on the part of the consumer. The company launched the first direct-to-consumer website that enabled consumers to access not only relevant information about their disease but available savings and support for their drug treatments. ( This consumer centric portal included free access to available drug adherence and savings programs direct from the manufacturer. With more than 2.4 million active members, the site has been featured on major news networks, and leading publications, such as The Wall Street Journal, LA Times, and AARP s Monthly Newsletter. The company plans to leverage their ability to offer a much wider inventory of virtual esamples and ecoupons by marketing these offers directly to opt-in patients by their disease state. company highlights The company recently received funding at $1.50 per share (from Vicis Capital). Electronic prescriptions will grow by 650% by 2015 due to medicare mandates and the subsidies being offered to care providers who automate the prescription process. SampleMD is the only system we are aware of that automates the process of drug sample management. This is a key issue as manufacturers are decreasing the size of their sales force, as almost half the doctors practices now will no longer allow drug salesman into their offices. SampleMD s average inventory was approximately 45 different drug samples or ecoupon offers at a time in mid-to-late The company now has closer to 70 offers and are adding 40,000-60,000 new users to their network in Q Q By the end of Q they expect the number of different drug offers to be close to 100. The company currently has $3m-$4m in open purchase orders to issue samples or co-pay discounts from over 60 of the biggest brand names in the drug industry. The key was building up an inventory of a wide variety of drugs that are top sellers. The system will now be stickier for new users coming into the system. The software can be fully integrated with any electronic medical record application or electronic prescription writing application which is a booming sector by itself. By having a growing amount of drug offers on widely prescribed drugs, and even 10,000 potential active users, the financial projections can be startling. EXCHANGE: OTCBB SYMBOL: OPRX RECENT PRICE: $ WEEK RANGE: $0.53-$1.60 AVERAGE DAILY VOLUME: 5,500 LAST 3 MONTHS FULLY DILUTED: SHARES & EQUIVALENTS 32M BALANCE SHEET: NO DEBT

2 company s future: SampleMD In 2010, the company developed their flagship software known as SampleMD a proprietary software-as-a-service (SaaS) application. SampleMD has quickly become a market leader for providing electronic drug discount coupons, drug sample vouchers, and complete electronic patient support tools that can be fully integrated with any electronic prescription writing application or electronic medical records application. SampleMD enables healthcare providers to review, add, and print coupons as well as electronically notifying the pharmacy of available co- pay discounts and free drug sample offerings applied via electronic ecoupons or on site printed vouchers submitted to the pharmacy by the patient. All of these features along with drug safety, and sales information & patient education materials are in this fully integrated software module, which resides right within the care provider s e-prescribing or EHR workflow software. The company generates revenue each time a care provider prints or electronically sends a coupon or sample voucher to a pharmacy. The drug manufacturer then pays the company $5.00 for every ecoupon or esample that is issued. There are also additional setup and reporting fees for each brand. This equates to 18-20% retention by patients, and is far higher than the more customary coupon utilization rates of 5-6% for coupons mailed or downloaded via the internet. The SampleMD system was initially designed to be an enabling technology that integrates with the networks of leading closed or restricted health systems. The closed or restricted practices do not allow drug sales personnel into their offices significantly limiting their access to drug samples that historically helped them get patients onto the correct medication. SampleMD is enabling these care providers to now search for available samples vouchers, coupon savings, patient educational support and formulary information for the types of medications they wish to prescribe directly from their desktop or Electronic Medical Record (EMR) systems. This ability to print sample vouchers for patients these closed systems are now better able to help patients get on and stay on their prescribed medications. The integration capabilities of SampleMD have enabled the company to partner with existing software companies that already provide electronic prescription applications or electronic health record (EHR) systems. This will provide a valuable and efficient marketing tool for the company in that it provides for large scale distribution opportunities for SampleMD in terms of care provider coverage. In an earlier test of its capabilities, SampleMD was integrated with select components of the eprescribe application operated by Allscripts Inc. (NASDAQ:MDRX). This integration provided access to more than 10,000 healthcare providers searching for a better way to access patient savings and support from within their eprescribing workflow. The company s initial success with this opportunity has resulted in Allscripts now integrating SampleMD (mid 2012) into all of their eprescribe workflow applications that serve 80,000 physicians. In late 2011, the company entered into strategic licensing agreements with other leading EHR software and e-prescribe software platforms. This will enable SampleMD to reach up to 250,000 health care providers. This is will allow SampleMD to expand its leadership position in distributing patient savings and support to more providers right within their prescribing workflow. SampleMD is now enabling the widest reach for drug manufacturers desperately seeking new ways to reach doctors due to traditional drug reps being restricted or limited to appointment only. Of equal importance is eprescribing expected to grow another 600% by 2015 reaching 2 billion annually in a market where SampleMD is the clear leader. Leveraging SampleMD s integrated technology within the prescribers workflow presents a very unique opportunity to engage prescribing clinicians with the over 200+ Electronic Health Record (EHR) systems to provide relevant information and patient support right at point of prescription. This includes informing doctors if an ecoupon is in the system at the same time the formulary displays, and allowing the prescriber to review and distribute patient savings; product information and educations support program(s). Page 2

3 The SampleMD competitive advantages are numerous for all parties including pharma, care providers, patients and even the pharmacies. By having one single proprietary platform to reach, manage and track any promotional programs to over 200 EHRs and 200,000 providers, millions of patients and thousands of pharmacies, this application is quickly growing into a branded source of quality services. SampleMD provides the manufacturer the ability to target promotion of right offer to right provider and patient by a matrix of options and rules. The system also enables the ability to provide one tracking and (real time) reporting system for multiple EMRs. SampleMD s coupon redemption rate has been four times the traditional print coupon or website download or direct mail media. Which means the manufacturer is getting a return, the provider is helping onboard a patient onto medication and the patient is getting the discount or sample value in savings. SampleMD will continue marketing to both software partners, and closed practices seeking the functionality to improve care for their patients. It will also provide the manufacturers with an exclusive channel for their drug samples and coupons, directly into leading closed health systems. SampleMD Services Offered: Direct to Provider Promotion of evoucher/co-pay programs at point of prescription Direct to Pharmacy enotification of distributed voucher or copay within erx Direct to Provider Promotion of Patient Education within prescribing workflow Developing Re-engagement of the Patient Post Fill to promote Adherence Direct to Consumer Enrollment into patient trial or adherence program erep Scheduler allowing providers to set up time slots and business rules for participating manufacturers to set up appointments via our portal (launching in 2012) Direct Distribution Interface from Rep to Doctor of evouchers/co-pay (launching in 2012) Side by Side testing within various channels of Various Patient Offers to maximize impact on Rx selection and fills Real Time Reporting Portal to measure utilization by channel, geography, program, and other unique user metrics Page 3

4 relevant industry dynamics New research shows that 76.5% of patients pick up their prescriptions at the pharmacy when the doctor e-prescribes, according to Surescripts Inc. (which handles almost all U.S. prescriptions). This percentage is seven (7%) percent higher than the pen-andpad manually written method is used. By looking at first-fills, or prescriptions that are not a refill of a previously used drug, researcher s analyzed 40 million prescription requests from 2008 to Collaborating with half a dozen drug stores and pharmacy-benefit managers, researchers compared the likelihood that people get their medications when physicians e-prescribe versus the traditional methods such as paper, fax or phone.* E-prescriptions now account for almost one-third of all prescriptions, totaling 149 million for the three-month period ending in September 2010, according to Surescripts.* The majority of office-based physicians, or 350,500 of them, are now use e-prescribing. This is a 72% increase from the previous year, according to Surescripts. * E-prescribing has tripled in the past three years as doctor s offices rush to meet federal requirements that will require all Medicare prescription submissions be electronic by * *This information is according to a Surescripts Inc. report that released early this year and featured in the Wall Street Journal. operational and sales strategies The company is a software development company and a sales and marketing company. The company currently has 15 employees and operates on a very lean culture with regards to salaries and overhead. The company has controlled development costs and overhead while revenue was initially starting to accrete in SampleMD is unique in that the users generally do not pay to use the software instead the drug companies pay OptimizeRx Corporation to enable them to have this extremely efficient channel directly to the care providers and patients. The revenue model is highly leveraged, whereby the company creates revenue every time an individual care provider uses SampleMD to dispense an ecoupon, printed coupon or esample voucher. The company s goal is to have in excess of 40,000 to 50,000 regularly active users in late 2012 that will have at that time, access to well over 100 widely prescribed drug coupon or sample offers at any given time. This matrix of users and lucrative discount coupons or free samples should help the company develop material amounts of ongoing brand loyalty amongst users as well as potentially lucrative amounts of operating income. The company expects total operating costs for 2012 will be less than $2,500,000, including more material programming & development to the SampleMD system to continue to improve and evolve its functionality. The company is also adding several sales people whose job it is to call on pharmaceutical manufacturers to obtain product marketing agreements which offer new drug coupon or sample offers within SampleMD. The marketing plan is to find and partner with any solid reputable willing software partner in the eprescription or EHR space that can provide reasonable distribution opportunities for SampleMD. In addition to vertical partnering with other applications, SampleMD was initially designed to be marketed to large closed private practices who would be motivated to have access to sample and coupon programs for their patients that had long since disappeared by way of the no visit policies that govern drug sales practices. The company believes there are in excess of 550,000 targeted physicians and even a larger number of staff members who represent the target user market for SampleMD. Through vigorous industry networking, the company will continue to partner with value added software partners who have existing users. The company already has a base of solid closed practices and continues to market to this segment as well. Page 4

5 intellectual property strategies All key aspects of our SampleMD promotional and drug offer development platforms are pending patent review. OPTIMIZERx is a licensed trademark. SampleMD is a licensed trademark The company s patent pending technology and process exclusively enables notification to the pharmacist of applied vouchers or coupon s, all right within the eprescription, through SampleMD s enotification option. The company s intellectual property is further developed significantly each month. The company expects to continue to file for broader process type patent applications as it continues to build functionality into this suite of software. App Number/Filing Date Brief Summary (Products Covered) Status S.N. 11/528,292 September 27, 2006 System for providing patient savings and promoting health care product sales Patent application pending. S.N. 61/277,161 September 21,2009 Virtual Sample Cabinet System and Method for Prescribing Drug Marketing Patent application pending management team David A. Harrell, Founder & Chairman David leads the company s overall strategic direction and new product development. Background includes two decades leading company management, sales, marketing and business development within the pharmaceutical and advertising industries. Prior to founding OPTIMIZERx Corporation, David served as Vice President of Business Development for Meridian--a top 40 healthcare and retail advertising agency. Within his ten years at SmithKline Beecham, David had several roles within the company s managed markets healthcare segment. David began his pharmaceutical career with Adria Laboratories in 1988 after graduating from Oakland University with a Bachelor of Science in Business Administration. H. David Lester, Chief Executive Officer David manages the daily business and operations for the company. David is a business veteran who has accumulated thirty years of executive experience in the areas of business, marketing, sales, operations and technology. Prior to accepting his new role with OptimizeRx, he held the title of Director, Consumer & Industrial Products Marketing for Deloitte LLP. During his tenure at Deloitte, he established Deloitte as a leader through innovative programs and strategic partnerships. Before Deloitte, he worked with Sun Microsystems as Global Director, Industry Strategy & Marketing. Mr. Lester s entrepreneurial and international experiences also include partnering in an engineering services company, co-founding a software development company and international expansion of new technology solutions within emerging markets. Throughout his career, Mr. Lester has also served on many associations as a proactive champion for building international technology standards, cyber security initiatives, trade policy, renewable energy, business tax reform, health care reform and sustainability. Terence J. Hamilton, SVP of Sales Terry leads overall sales for the company, with more than 22 years of experience working in the pharmaceutical and biotech arenas within various sales, marketing and managed markets management positions. Before joining OPTIMIZERx, he worked as a Director in Managed Markets for MedImmune - one of the world s leading biotech companies. Prior to that, Mr. Hamilton was a National Account Manager for Glaxo SmithKline pharmaceuticals and has held many positions within the pharmaceutical and biotech industries, including District Manager, Brand Manager, Managed Market Specialist, Contract Manager, Government Account Manager. He has vast expertise and leadership in helping clients expand market access and adherence. Page 5

6 management team (cont d) Shad Stastney, Director Shad Stastney manages the company s financing and acquisition/partnerships and is a founding partner of Vicis Capital LLC. He graduated from the University of North Dakota in 1990 with a B.A. in Political Theory and History, and from Yale Law School in 1994 with a J.D. focusing on corporate and tax law. From 1994 to 1997, he worked as an associate at Cravath, Swaine and Moore in New York, where he worked in the tax group and in the corporate group, focusing on derivatives. In 1997, he joined CSFB s then-combined convertible/equity derivative origination desk. From 1998 through 2001, he worked in CSFB s corporate equity derivatives origination group, eventually becoming a Director and Head of the Hedging and Monetization Group, a joint venture between derivatives and equity capital markets. In 2001, he jointly founded Victus Capital Management, LP, and in 2004, he jointly founded Vicis Capital LLC. Blake Whitney, Sr. Advisor Blake s long experience is in the development of business opportunities in the healthcare industry. He was the co-founder, CEO and Chairman of MDdatacor (a GA corp.) and was also on the founding team and the first president of WebMD. He s raised venture capital, executed significant contracts with medical device, pharmaceutical and health plan customers. He helped lead WebMD, health s homepage as it created the health information transformation from the bookshelf to the computer desktop. At WebMD he managed explosive company growth, merged with Healtheon (now WebMD Health Corp. NASDAQ: WBMD). Previously, Mr. Whitney was the President of Quality Diagnostic Services, Inc., (QDS). Nilesh Patel, PhD, Technology Advisor Nilesh serves as the company s overall technology leader responsible for the development, testing and maintenance of its proprietary technology. Nilesh is a recognized leader in cross platform application architecture, connected mobility and overall design and development in education, healthcare and biotech. This document contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words estimate, possible and seeking and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. Page 6